CPT 89049Laboratory

Chct for mal hyperthermia

CPT code 89049 covers laboratory testing to determine if a patient has malignant hyperthermia susceptibility, a rare genetic condition that causes severe reactions to certain anesthesia drugs. This specialized test analyzes muscle tissue samples to identify patients at risk during surgery.

Showing rates for

National Average

Base Medicare rate

$281.41

This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.

RVU breakdown

Work RVU

1.4

PE RVU (NF)

7.13

MP RVU

0.17

Total RVU

8.7

Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High

NCCI bundling edits

Loading bundling edits…

Billing tips

Verify non-facility versus facility status carefully; bill in non-facility setting when possible as this yields $281.41 versus $59.19 in facility setting
Impact: Proper setting selection impacts reimbursement by $222.22 (74% reduction in facility setting)
Document specimen viability and transport time meticulously; specimen must reach laboratory within 4-6 hours of biopsy and remain viable for contracture testing
Impact: Failed specimens due to transport delays result in 100% denial and require repeat biopsy procedure
Coordinate billing between surgical biopsy provider and laboratory; ensure muscle biopsy CPT code (20200-20206) is billed separately by surgeon while laboratory bills 89049
Impact: Prevents bundling denials and ensures both services receive appropriate payment
Submit detailed documentation of testing protocol including caffeine and halothane concentrations, contracture thresholds, and diagnostic criteria applied (European or North American MH Group protocols)
Impact: Reduces medical necessity denials by 65-80% when comprehensive methodology is documented
Include supporting clinical documentation such as family pedigree, prior anesthetic reactions, or elevated CK levels to establish medical necessity for this high-cost test
Impact: Strengthens prior authorization approval and reduces post-payment audit recoupment risk
Bill only one unit per patient encounter regardless of number of muscle fascicles tested; the code represents the complete contracture testing battery, not per-specimen testing
Prevents overbilling denials and compliance violations; multiple units trigger automatic audits

Live Field Datano reports yet

Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.

Working with CPT 89049?

Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.

Help build the field knowledge

MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.

Related actions

Frequently asked questions

What is CPT code 89049 used for?

CPT code 89049 is used for contracture testing on muscle biopsy specimens to diagnose malignant hyperthermia susceptibility. This laboratory test measures how muscle tissue responds to halothane and caffeine exposure to identify patients at risk for severe anesthetic reactions.

How much does Medicare pay for CPT 89049 in 2025?

Medicare pays $281.41 for CPT 89049 in non-facility settings and $59.19 in facility settings under the 2025 Physician Fee Schedule. The significant difference reflects the technical resources required in independent laboratory settings.

Does CPT 89049 require prior authorization?

Most commercial payers and Medicare Advantage plans require prior authorization for CPT 89049 due to its high cost and specialized nature. Traditional Medicare does not require prior authorization but does require medical necessity documentation to support payment.

Can CPT 89049 be billed with genetic testing codes?

Yes, CPT 89049 can be billed separately from genetic testing codes (such as 81406 for RYR1 or CACNA1S gene sequencing) as they represent different diagnostic methodologies. Contracture testing remains the gold standard when genetic testing is negative or equivocal.

What is the difference between facility and non-facility rates for 89049?

The non-facility rate ($281.41) applies when testing is performed in independent laboratories or hospital outpatient settings, while the facility rate ($59.19) applies to hospital inpatient or on-campus provider-based departments. The difference reflects overhead costs included in the non-facility rate.

How many RVUs is CPT code 89049 worth?

CPT 89049 has a total of 8.7 RVUs in 2025, consisting of 1.4 work RVUs, 7.13 non-facility practice expense RVUs (0.26 facility PE RVUs), and 0.17 malpractice RVUs. This high RVU value reflects the technical complexity and expertise required.

What documentation is needed to bill CPT 89049?

Documentation must include specimen viability confirmation, detailed testing methodology with caffeine and halothane concentrations, quantitative contracture measurements, diagnostic interpretation according to established protocols, and clinical justification including family history or prior anesthetic reactions supporting medical necessity.